ʻO Gliclazide MV 30 a me 60 mg: nā kauoha no ka hoʻohana ʻana

ʻO Gliclazide MV: ʻōlelo aʻoaʻo no ka hoʻohana a me nā loiloi

Ka inoa Latin: Gliclazide MV

ATX Code: A10BB09

ʻO kēia mea kūpono: gliclazide (gliclazide)

Mea Hana: LLC Ozon, LLC Atoll (Lūkini)

Hoʻohou i ka wehewehe a me ke kiʻi: 01/14/2018

ʻO nā kumukūʻai ma nā lāʻau lapaʻau: mai ka 81 mau rubles.

ʻO ka Gliclazide MV kahi lāʻau lapaʻau hypoglycemic waha.

E hoʻokuʻu i ke ʻano a me ka ʻano

Hoʻololi ʻia ka Gliclazide MV i ke ʻano o nā papa me ka hoʻokuʻu ʻia: cylindrical, biconvex, keʻokeʻo me kahi ʻono ʻalani a i ʻole keʻokeʻo paha, hiki i nā ʻāpana marbling (10, 20 a i ʻole 30 mau ʻāpana i loko o ka alumini contour a i nā pōpoki polū polyvinyl chloride, 1, 2, 3, 4, 5, 6, 10 mau pākeke i kahi pōpō kāleka, 10, 20, 30, 40, 50, 60, a i ʻole 100 mau poloka.

Aia ka hoʻonohonoho ʻana o ka papa pākuhi 1:

• ʻO ka waiwai koʻikoʻi: gliclazide - 30 mg,
• ʻO nā mea kōkua: hypromellose - 70 mg, colloidal silicon dioxide - 1 mg, microcrystalline cellulose - 98 mg, magnesium stearate - 1 mg.

Lapaʻau lāʻau

ʻO Glyclazide kahi derphative o ka sulfonylurea ka mea he hypoglycemic waiwai a manaʻo ʻia no ka hoʻokō waha. ʻO ka ʻokoʻa mai nā lāʻau lapaʻau ma kēia ʻāpana, ʻo ke kahe ana o kahi apo heterocyclic N-loaʻa me ka mea paʻa endocyclic.

Hoʻopau ka Gliclazide i ke koko glucose, ka mea e hōʻeuʻeu i ka hana insulin e nā beta beta o nā mokupuni o Langerhans. Ke hoʻonui nui nei o ka C-peptide a me ka insulin postprandial e kū nei ma hope o 2 mau makahiki o ka mālama ʻana. E like me nā mea like o nā derebatives sulfonylurea, ʻo kēia hopena ma muli o ke ʻano ikaika loa o ka cells-cell o nā mokupuni o Langerhans i ka hōʻeuʻeu ʻana i ka glucose, i hana ʻia e like me ke ʻano physiological. ʻAʻole pili wale ka Gliclazide i ka metabolism ketone, akā ua hoʻonāukiuki i nā hopena hemovascular.

I ka poʻe maʻi me ka diabetes mellitus type 2, kōkua ke gliclazide e hoʻihoʻi i ka mua o ka hoʻokolohua o ka hana o ka insulin, kahi hopena o ka hoʻopiʻi glucose a hoʻoulu hou i ka lua o ka hana o ka huna ʻana o ka insulin. Hoʻonui ʻia ka hoʻonui nui o ka synthesis insulin me ka pane ʻana i ka hoʻoulu ʻia e ka maʻi glucose a ʻai ʻole paha i ka meaʻai.

ʻO ka hoʻohanaʻana o gliclazide e hōʻemi i ka hopena o ka hoʻomohala ʻana i ka moku thrombosis liʻiliʻi ma o ka hana ʻana i nā hana hiki ke hoʻonāukiuki i ka hoʻomohala ʻana o nā hoʻopiʻi i nā maʻi me ka maʻi mellitus, he hōʻemi i loko o nā manaʻo o nā mea hoʻohālikelike platelet (thromboxane₂, beta-thromboglobulin), kahi pale o ka hōʻiliʻili o ka pā platelet a me ka hōʻuluʻulu ʻana, me ka hoʻopiʻi ʻana i ka hoʻihoʻi hou ʻana o ka hana fibrinolytic ʻano o ka votone endothelium, a me ka hoʻonui ʻana i ka hana o plasminogen, he mea hoʻoikaika ka iwi.

ʻO ka hoʻohana ʻana o ka glycazide i hoʻokuʻu ʻia, ʻo ka target glycosylated hemoglobin (HbAlc) i hōʻemi ʻia i ka 6.5%, me ka mana o ka glycemic control e like me nā hoʻokolohua kūpono i ke kulekele, hiki ke hōʻemi i ka pilikia o ka makro-a me nā hoʻopiʻi o ka microvascular i hoʻopili ʻia i ka diabetes type 2 control

ʻO ka hana ʻana o ka mana glycemic intensive ka mea i kuhikuhi i ka gliclazide (ʻo ka awelika o ka lā maʻamau e 103 mg) a me ka hoʻonui ʻana i kona momona (a hiki i ka 120 mg i kēlā me kēia lā ke hele i ke ʻano maʻamau o ka maʻi ma ka ʻaoʻao (a i ʻole ʻoi aku) ma mua o ka hoʻohui ʻana iā ia me kekahi lāʻau lapaʻau hypoglycemic (ma ka laʻana, ka insulin, metformin thiazolidinedione derivative, alpha glucosidase inhibitor). ʻO ka hoʻohana ʻana o gliclazide i ka hui o nā mea maʻi e lawe ana i ka kontrol glycemic intensive (ma ka awelika, ʻo ka waiwai HbAlc o 6.5% a me ka nui o ka lōʻihi o ka nānā ʻana he 4.8 mau makahiki), i hoʻohālikelike ʻia me ka hui o nā mea maʻi e hoʻomalu nei i ka mālama maʻamau (ʻo ka makeʻana o ka HbAlc waiwai he 7,3% ), ua hōʻoia e pili ana ka hoʻohaʻahaʻa kūpono o ka hōʻuluʻulu ʻana o ka hoʻopiʻi a me ka hoʻopiʻi macrovascular (ka nui o ka 10%) ma muli o ka hōʻemi nui ʻana o ka hopena e pili ana i ka hoʻomohala nui ʻana o nā hoʻopiʻi microvascular nui (ma ka 14%), manawa Itijah a me ka Holomua o microalbuminuria (9%),ʻaʻa puʻuwai complications (11%), hoouka kaua a me ka Holomua o nephropathy (21%), a me ka hooulu ana o macroalbuminuria (30%).

Ke koho ʻana i ka gliclazide, loaʻa i ka maʻi glycemic intensive ka loaʻa o nā pono nui i hoʻoholo ʻole ʻia e nā hopena o ka mālama ʻana me nā lāʻau antihypertensive.

Lapaʻau lāʻau

Ma hope o ka lawelawe waha, ua hoʻokomo ʻia ke glycoside i ka hana kūwili e 100%. Hoʻonui mau kona kikoʻī i loko o ke koko koko me nā hola 6 mau mua, a hoʻomau mau ka paʻa ʻana no 6-12 mau hola. ʻO ka laulā a i ʻole ka helu o ka hoʻopili ʻana o ka gliclazide ke kūʻokoʻa nei i ka ʻai o ka meaʻai.

Ma kahi o 95% o ka mea hana e hoʻopaʻa ai i nā protein plasma. ʻO ka nui o ka hoʻoili e pili ana i 30 mau lita. Hoʻomaopopo ka Gliclazide MV ma kahi waihona o 60 mg hoʻokahi i ka lā e hiki iā ʻoe ke mālama i ka naʻau therapeutic o gliclazide i loko o ke koko koko no 24 mau hola a keu paha.

Hoʻopau nui ka hana gliclazide i loko o ka puʻuwai. ʻAʻole hoʻoholo ʻia ka pharmacologically hoʻoikaika o kēia mea i ka plasma. Hoʻolaha nui ʻia ka Gliclazide ma o nā ʻōpū ma loko o ke kinipona i loko o ke ʻano o nā metabolites, kahi kokoke i 1% i hoʻoponopono ʻia i ka urine. ʻO ka hapalua hapalua he 16 mau hola (ke hoʻololi ka hōʻailona mai ka 12 a 20 mau hola).

Ua hoʻopaʻa ʻia ka pilina laina ma waena o ka loaʻa o ka lāʻau lapaʻau (ʻaʻole iʻoi aku ma mua o 120 mg) a me ka wahi i lalo o ka curacokinetic curve "concentration - manawa". I ka poʻe maʻi ma waena, ʻaʻohe mau loli nui i ka maʻi i loko o nā laina pharmacokinetic.

Nā hōʻailona no ka hoʻohana ʻana

Wahi a nā ʻōlelo kuhikuhi, ua hoʻākāka ʻia ʻo Gliclazide MV no ka mālama ʻana i ka hōʻemi pono o ka maʻi diabetes mellitus type 2 (non-insulin-dependant) me nā hōʻike mua o ka microangiopathy diabetes.

Hoʻohana ʻia ka lāʻau lapaʻau e pale i nā pilikia o ka microcirculatory (i ka manawa like me nā derivatives a sulfonylurea).

Nā Hoʻohui

• ʻO ka maʻi diabetes mellitus 1 (ke hilinaʻi-insulin),
• ʻO kaʻeha hōʻeha o ke akepaʻa a me nā ukana,
• Ketoacidosis
• ʻO ka coma maʻi maʻi a me ka precoma
• Hoʻohana me ka deridatives imidazole (me ka miconazole),
• Hypersensitivity i sulfonamides a me sulfonylureas.

ʻAʻole hoʻohana ʻia ka hoʻohana ʻana o Glyclazide MV no ka lactating a me nā wahine hāpai.

Nā ʻōkuhi no ka hoʻohana ʻana i ka Gliclazide MV: kaʻina a me ka maʻi

Lawe ʻia ka Gliclazide MV ma mua o ka papaʻaina.

ʻO ka hoʻonui pinepine ʻia o ka lawe lāʻau i 2 mau lā i ka lā.

E hoʻoholo ana ke kauka i ka laʻikahi i kēlā me kēia lā, ma ke ʻano o nā hōʻike lapaʻau o ka maʻi a me ka glycemia, ma kahi ʻōpū ʻole a me 2 mau hola ma hope o kahi pāʻina.

Ma ke ʻano he kānāwai, ʻo ka dosis mua loa he 80 mg i kēlā me kēia lā, ʻo ka awelika awelika he 160-320 mg i kēlā me kēia lā.

Nā hopena hopena

I ka wā o ka hoʻohana ʻana o Gliclazide MV, hiki iā ia ke hoʻomohala i nā maʻi mai kekahi mau ʻōnaehana o ke kino:

• Pūnaehana digestive: līkuhi - nausea, anorexia, ʻeha, maʻiʻaʻi, ʻeha ʻo epigastric,
• Pūnaehana endocrine: me kahi overdose - hypoglycemia,
• ʻO ka ʻōnaehana Hematopoietic: i kekahi mau hihia - thrombocytopenia, leukopenia a agranulocytosis, anemia (maʻamau hoʻohuli),
• He maʻi kūlohelohe: hina, ʻiliʻili.

Ke keu

ʻO kahi overdose o MV Glyclazide hiki ke hoʻonāukiuki i ka hoʻomohala ʻana o ka hypoglycemia, a ma nā hihia koʻikoʻi, hypoglycemic coma.

Hoʻomaʻamaʻa ʻia nā hōʻailona o ke kaumaha o ka hypoglycemia e nā loliʻai, ke koho ʻana a me nā koho a i ʻole ka ʻoni. E hoʻomau ka mālama pono ʻana i ke ʻano o ka mea maʻi a hiki i ka lilo ʻana i hoʻoweliweli i ke ola a me ke olakino. Hiki i ka maʻi hypoglycemic hopena ke ulu pū, i hui pū ʻia e ka māho, coma, a i ʻole nā ​​pilikia ʻē aʻe o ka pūnaehana sentral. Inā hele mai ia mau ʻōuli, e pono e mālama ʻia i ka mālama lāʻau lapaʻau a koi ʻia ka hale hoʻomaha.

Inā noʻonoʻo ka mea maʻi i ka hypoglycemic coma a i ʻole he mea nona ia, pono ia e hāʻawi (intravenously, jet) 50 ml o kahi kūmole kulekele 40% (dextrose). Ma hope o ke kuhi ʻia, kahi 5% dextrose i hoʻopaʻa ʻia i ka intravenously, hiki iā ʻoe ke mālama i ke kaila o ka glucose i loko o ke koko (e pili ana iā ia 1 g / l). Pono kiaʻi ʻia ka ʻike o ka glucose koko a kia hoʻomau mau ʻia ka mea maʻi i ka liʻiliʻi o 2 mau lā ma hope o ka loaʻa ʻana o kahi maʻi maʻi. ʻO ka pono no ka nānā hou ʻana i nā hana nui a ka mea maʻi e hoʻoholo hou ʻia e kona kūlana.

No ka mea pili ka gliclazide i kahi nui i ka protein plasma, ʻaʻohe pono o ka dialysis.

Nā ʻōlelo kikoʻī

I ka mālamaʻana i ka mellitus non-insulin-hilinaʻi, pono e hoʻohana like ʻo Gliclazide MV i ka manawa like me ka meaʻai haʻahaʻa-calorie me kahi haʻahaʻa haʻahaʻa o nā calcium.

I ka wā mālama, pono ʻoe e kiaʻi pinepine i nā kukuna o kēlā me kēia lā i nā pae glucose, a me ka pae o ka glucose i loko o ke koko ma kahi ʻōpū ʻole a ma hope o ka ʻai.

Me nā interventions kaʻaila a i ʻole decompensation o ka mellitus o ka maʻi mellitus, pono ke noʻonoʻo pono ʻia ka hoʻohana ʻana i ka hoʻomākaukau o ka insulin.

I ka hihia o ka hypoglycemia, inā ua ʻike ka mea maʻi, he glucose (a he ʻaila gula paha) e hoʻohana ʻia me ka ʻōlelo maʻamau. Ma kahi e pau ai ka ʻike, glucose (intravenously) a i ʻole glucagon (subcutaneously, intramuscularly a intravenously) paha e lawelawe. I mea e pale ai i ka hoʻomohala hou ʻana o ka hypoglycemia ma hope o ka hoʻihoʻi ʻana i ka ʻike, pono ke hāʻawi ʻia ka mea maʻi i nā meaʻai momona.

ʻAʻole hoʻohana ʻia ka hoʻohana pinepine ʻana o gliclazide me cimetidine.

Me ka hoʻohana pū ʻana o ka gliclazide me ka verapamil, pono ia e kiaʻi pinepine i ka pae o ka glucose i ke koko, me ka acarbose, ka nānā akahele a me ka hoʻoponopono ʻana i ka hoʻoponopono ʻia ʻana o nā hana a ka lawehala o ka hypoglycemic pono.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a me nā mīkini paʻakikī

ʻO ka poʻe maʻi e lawe ana iā Glyclazide MV pono e ʻike i nā hōʻailona hiki i ka hypoglycemia a ua haʻi aku e pili ana i ka pono e makaʻala i ka wā e hoʻokele a hana ana i kekahi mau hana e koi ai i nā ʻano psychomotor koke, me ka hoʻomaka ʻana o ka mālama ʻana.

ʻO nā hiʻohiʻona maʻamau o ka lāʻau

ʻO Gliclazide MV kahi mea kikowaena waha e waiho nei i kahi o ka lua o ka holony o ka sulfonylurea. Ua hoʻohana nui ʻia nā hoʻomākaukau o kēia pūʻulu i ka hana lapaʻau, mai ka makahiki 1950. I ka wā o ke Kaua Honua II, ua hoʻohana ʻia kēia mau lāʻau e hakakā i nā maʻi like ʻole, a na ka manawa wale nō i loaʻa ka hopena hypoglycemic.

ʻO ka aina o ka hana o ka lāʻau lapaʻau ʻo Rūsia. ʻO Glyclazide MV 30 mg i loko o nā papa he mea hoʻokahi wale nō ke ʻano o ka lāʻau lapaʻau e hana ai. ʻO ka MB acronym e kū no ka Hoʻolaha Hou. Hoʻomaopopo kēia i nā ʻaina o nā papa o ka MV i loko o nā ʻōpū no ʻekolu mau hola, a laila e komo i ke kahe a hoʻokaʻahaʻa i ka glucose i ke koko. He hopena hōʻoluʻolu loa kēia mau lāʻau i ka hoʻemi ʻana i ke kō, no laila, ʻoi aku ka liʻiliʻi o ke alakaʻi ʻana i ke kūlana o ka hypoglycemia (wale nō 1% o nā hihia).

ʻO ka lāʻau lapaʻau ʻO Gliclazide MV i ka wā hoʻohana he hopena maikaʻi loa ia o ke kino o ka mea maʻi:

1. Ua hoʻonāukiuki i ka hana o ka insulin e ka pancreas.
2. Hoʻēmi i ke kō koko.
3. Loaʻa kahi hopena huna o ka insulin i ka glucose.
4. Hoʻonui i ka hikiʻole o ka iwi me ka hormone.
5. Mālama i ka pae o ke glycemia ma kahi ʻōpū ʻole.
6. Hoʻemi i ka hana glucose glucose.
7. Hoʻopilikia i nā microcirculation a me ka metabolism i kālaiʻu.

Eia kekahi, ʻaʻole e hōʻemi ka lāʻau lapaʻau i nā hopena o nā palaka koko i nā moku.

Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau

Ma kēia hihia, ʻaʻole hiki ke hoʻomaʻamaʻa iā ʻoe iho, ʻo ke kauka wale nō, ma hope o ke kaupaona ʻana i ka pono o ka lāʻau a me kona pōʻino i ke kino o ka mea maʻi, hiki iā ia ke kuhikuhi i nā papa papa Glyclazide.

Ma hope o ka nīnau ʻana i ke kauka, pono ʻoe e kūʻai i kahi lāʻau lapaʻau, ke ʻeke o ka 60 papa. Hoʻohana ʻia ka lāʻau lāʻau i ia mau hihia:

1. Ma ka hoʻomaʻamaʻa ʻole o nā maʻi like ʻole o ka insulin, i ka manawa a me ka hoʻokūkū kūpono e hiki ʻole ai i nā mea hōʻemi me ka hoʻohaʻahaʻa ʻana i ka hoʻoliʻiliʻi koko.
2. No ka pale ʻana i nā hopena o ka pathology - nephropathy (hana i kau ʻia ka hopena) a me ka retinopathy (maʻi i nā retina o nā makamae).

Loaʻa nā ʻōlelo aʻoaʻo e pili ana i ka ʻike āpau e pili ana i nā papa, pono ʻoe e heluhelu pono. ʻO ka dosis ma mua no nā poʻe maʻi e hoʻomaka wale ana i ka mālama ʻana, a no ka poʻe ma luna o ka makahiki he 65 he 30 mg i kēlā me kēia lā. Ua hoʻopau ʻia lākou i ka wā kakahiaka. Ma hope oʻelua mau pule o ka lapaʻau, hoʻoholo ke kauka inā hoʻonui i ka nui. ʻElua mau mea e hoʻohālikelike i kēia - nā hōʻailona kuhikuhi a me ka nui o ka maʻi diabetes. Ma keʻano holoʻokoʻa, ʻokoʻa ka hopena mai 60 a 120 mg.

Inā haʻalele ka mea maʻi i ka lāʻau lapaʻau, a laila ʻaʻole pono ka maʻa ʻelua ʻelua ma kekahi hihia. Inā aia e hoʻololi i ka intake o Gliclazide MV me nā wai e hoʻohiolo ana i ka hilahila, a laila e loli ka mālama ʻana mai ka lā aʻe. Hiki i kēia hōʻuluʻulu me nā metformin, insulin, a me nā inhibitors alpha glucosidase. ʻO nā maʻi me ka hōʻemi a ke kaulike maʻamau e lawe i nā like like. ʻO kēlā mau mea maʻi e pilikia ana i ka hypoglycemia e hoʻohana i ka lāʻau lapaʻau me nā haʻahaʻa haʻahaʻa loa.

Pono e mālama ʻia nā papa ma kahi wahi i ʻike ʻole ʻia no nā keiki liʻiliʻi, i kahi mahana wela ʻole o ka 25C. ʻOi ʻia ka lāʻau lapaʻau i ʻekolu mau makahiki.

Ma hope o ka lā pau, ua pāpā ʻia ʻole kāna hoʻohana ʻana.

ʻO ke kumukūʻai a me nā analog o ka lāʻau lapaʻau

No ka mea ua hoʻopuka ʻia kēia lāʻau lapaʻau e ka mea hana hale, ʻaʻole kiʻekiʻe loa kona kumukūʻai. Hiki ke kūʻai ʻia ka lāʻau lapaʻau ma ka hale kūʻai a kauoha ʻia i ka pūnaewele ma kahi hale kūʻai pūnaewele, ʻoiai ʻo ke hōʻike ʻana i ke ʻano o ke kauka kauka. ʻO ke kumu kūʻai o ka lāʻau lapaʻau ʻo Gliclazide (30 mg, 60 mau ʻāpana) mai nā 117 a 150 mau rubles. No laila, ʻo kēlā me kēia me ka uku kālā e hiki iā ia.

ʻO nā hui pū ʻana o kēia lāʻau lapaʻau ka mea e loaʻa ai i ka gliclazide mea waiwai e hana nei. ʻO kēia me Glidiab MV, Diabeton MV, Diabefarm MV. Pono e hoʻomaopopo ʻia he nui loa nā kumukūʻai Diabeton MV (30 mg, 60 mau ʻāpana): ʻo ka uku kumukūʻai ma 300 mau rubles. A aneʻa like ka hopena o kēia mau lāʻau.

I ka hopena i loaʻa i ka mea maʻi nā contraindications i ka gliclazide o ka mea a i ʻole ka hopena o ka lāʻau lapaʻau, pono e loli ke kauka i ka regimen mālama. No ka hanaʻana i kēia, hiki iā ia ke kākau i kahi lāʻau lapaʻau like, e hoʻohua ai hoʻi i ka hopena hypoglycemic, no ka laʻana:

• ʻO Amaryl M a i ʻole Glemaz me ka mea hoʻonāukiuki kōmū.
• ʻO Glurenorm me ke ʻano glycidone ikaika,
• ʻO Maninil me ka huaila glibenclamide kumu.

ʻO kēia kahi papa inoa piha o nā ʻike āpau, hiki ke ʻike ʻia ka ʻike kikoʻī ma ka Pūnaewele a i ʻole e nīnau i kāu kauka.

Ke koho nei kēlā me kēia maʻi i ka hopena maikaʻi e pili ana i ʻelua mau mea - ke kumu kūʻai a me ka hopena therapeutic.

Loaʻa nā manaʻo maʻi e pili ana i ka lāʻau lapaʻau

I kēia manawa, hoʻohana nui nā lāʻau pili i ka pūʻulu o nā derivatives sulfonylurea lua, e komo pū i ka lāʻau lapaʻau Gliclazide MV. ʻO kēia ma muli o kaʻoiaʻiʻo inā ʻoiai he nui nā hopena pā, ua hōʻemi nui ʻia lākou.

Ua hōʻike ʻia nā noiʻi ʻepekema i ka hopena maikaʻi o ka lāʻau ma ka microcirculation. Eia kekahi, pale ka lāʻau i ka hoʻolālā ʻana o nā hoʻopiʻi he nui.

• nā pahuhopu microvascular - retinopathy a me nephropathy,
• maʻi pālahalaha microangiopathy,
• māhuahua kaiʻaiʻaiʻai,
• nalowale o ke ʻano vascular.

ʻO ka hoʻohālikelike ʻana i nā loiloi o nā maʻi he nui, hiki iā mākou ke hoʻolauna i kekahi mau ʻōlelo hoʻolālā no ka hoʻohana ʻana i nā lāʻau lapaʻau:

• ʻoi aku ka maikaʻi o nā papa maʻa ma hope o ka ʻaina kakahiaka.
• ʻAi ʻia ka ʻaina kakahiaka i nā kalapika,
• ʻaʻole hiki iā ʻoe ke pololi i ka lā a pau,
• ke loaʻa nei i ke ʻano kino, pono ʻoe e hoʻololi i ka dosage.

Eia kekahi, ʻo ka loiloiʻana o kekahi mau maʻi maʻi e hōʻike ana i ka hoʻopili ʻana i ka ʻai haʻahaʻa-calorie a me ka hoʻokō nui ʻana i ke kino ma ke ʻano he hypoglycemia. Ua pili kēia i nā mea nāna i inu ʻona i ka wā e lawe nei i nā paila. ʻO ka loaʻa ʻana o ka haʻahaʻa o ka hoʻokaʻa koko i loko o nā kānaka kahiko ʻo ia.

Ke waiho nei i ka maʻi maʻi i kā lākou ʻōlelo a ua maʻalahi ka lāʻau i ka hoʻohālikelike ʻia i ka gliclazide konane, ʻo ka nui o ka nui o ka nui o ka nui. Hāʻawi i kahi wai hoʻokahi i kēlā me kēia lā ka hopena o ka wikiwiki a me ka maikaʻi, hoʻohaʻahaʻa i ka pae glucose i maikaʻi. Akā, aia kekahi mau hihia i hope o ka hoʻohana mau ʻana i ka lāʻau (e pili ana i 5 mau makahiki), ua lilo ka hopena, a ua kauoha ke kauka i nā lāʻau lapaʻau ʻē aʻe e hoʻololi piha i ka Gliclazide MV a i ka lāʻau paʻakikī.

ʻO Gliclazide MV kahi mea maikaʻi e hoʻomaʻamaʻa hypoglycemic maikaʻi e hōʻemi i ka puna koko. ʻOiai aia kekahi mau contraindications a me nā hopena hopena, ʻo ka loaʻa o ka hopena maikaʻiʻole he 1%. ʻAʻole pono ka mea maʻi e hoʻōla ponoʻī, ʻo ke kauka wale nō, i ka ʻike ʻana i nā ʻano kūʻokoʻa o ka mea maʻi, hiki iā ia ke kuhikuhi i kahi lāʻau maikaʻi. I ka loaʻa ʻana o ka maʻi mellitus type 2 me ke kōkua o Gliclazide MV, he mea pono hoʻi ia e hoʻokō pono i nā meaʻai kūpono a me ke ʻano hana. No laila, ka nānā ʻana i nā lula a pau, hiki i ka mea maʻi ke hoʻomau i kēia maʻi i loko o nā "pale hedgehog" a pale iā ia mai ka mālama ʻana i kona ola!

Hāʻawi ʻia ka ʻike ma Gliclazide MV ma ka wikiō ma kēia ʻatikala.

ʻO Glyclazide, ka ʻōlelo aʻoaʻo no ka hoʻohana ʻana (Ke ʻano a me ke ʻano)

Nā papa papa glyclazide i kuhikuhi ʻia ma loko o kahi wai no ka lā mua o 80 mg, lawe ʻia 2 mau manawa i kahi lā 30 mau minuke ma mua o ka papaʻaina. I ka wā e hiki mai ana, ua hoʻoponopono ʻia ke ʻano, a me ka nui o ka hoʻohana ʻana i kēlā me kēia lā he 160 mg, a ʻo ka nui he 320 mg. Hiki ke nānā aku nā papa palapala Glyclazide MB i nā papa hoʻoiho maʻamau. ʻO ka hopena o ka hoʻololi a me ka ʻona i kēia hihia e hoʻoholo ʻia e ke kauka.

Glyclazide MB 30 mg e lawe 1 mau lā i ka wā kakahiaka kakahiaka. Hoʻololi ʻia kahi hoʻololi ʻana ma hope o 2 mau pule o ka mālama ʻana. Hiki iā 90 -120 mg.

Inā nalowale ʻoe i ka paila ʻaʻole hiki iā ʻoe ke lawe i ʻelua pālua. I ka wā e hoʻololi hou ai i kahi lāʻau lapaʻau hoʻoilo wai hou me kēia, ʻaʻole pono ka manawa o ka hoʻololi - hoʻomaka lākou e lawe i ia lā aʻe. Malia paha kahi hui me nā biguanides, insulinnā mea paʻa alpha glucosidase. No ka māmā ke maʻalahi pilikia kūlohelohe koho ʻia ma nā palapala like. I nā poʻe maʻi me ka pilikia o ka hypoglycemia, hoʻohana liʻiliʻi ʻia.

Hōʻike ʻia ka overdose e nā hōʻailona o ka hypoglycemia: ʻeha, ka ʻeha, ka nāwaliwali koʻikoʻi, nā luhi, nā palpitations, hoʻonui i ke koko, arriraliahiamoe hoʻomohalahoʻonāukiuki, hoʻonāukiuki, lohi i ke kūhea ʻana, ʻike maka a me ka ʻōlelo, hāpauāhāhuʻe nahoa, brieociaianalowale o ka ike ana.

Me ka haʻahaʻa hypoglycemiame ka ʻike ʻole ʻole o ka naʻau, hoʻemi i ka nui o ka lāʻau o ka lāʻau a hoʻonui paha i ka nui o nā huamina i hāʻawi ʻia me nā meaʻai.

I nā kūlana hypoglycemic koʻikoʻi, pono ka mālama hospitalization a me ke kōkua ʻana: iv 50 ml o kahi hoʻonā glucose 20-30%, a laila he 10% dextrose a i ʻole ka hopena glucose i ka wai. I loko oʻelua mau lā, ka kiaʻi ʻia ka pae glucose. Kāolē pono ole ole.

Hoʻohana me ʻO Cimetidinee hoʻonui ai i ka ʻike gliclazidehiki iā ia ke alakaʻi i ka hypoglycemia koʻikoʻi.

Ke noi ʻia me Verapamil pono ʻoe e kāohi i ka pae o ka glucose.

Hoʻohālu ʻia ka hopena hypoglycemic i ka wā i hoʻohana ʻia me paʻakaikāhea Pyrazolone, sulfonamides, caffeine, Phenylbutazone, Theophylline.

ʻO ka hoʻohana ʻana o nā beta-blocker non-koho ākea ka hoʻonui ʻana i ka pilikia hypoglycemia.

Ke noi Acarbosehōʻailona hoʻohui hoʻohui hypoglycemic.

Ke hoʻohana nei iā GCS (me ka hoʻohana ʻana i nā ʻano o waho o ka noi) pani ʻia, hoʻoiho, estrogena progestins, Diphenin, Rifampicinua hoʻemi ʻia ka hopena haʻahaʻa hilo o ka lāʻau lapaʻau.

Ma ke ana o ka lōʻihi ma mua o 25 C.

ʻO Glidiab MV, ʻO Glyclazide-Akos, Diabinax, I Ka Kūʻai Diabeton, Diabetalong, Hula.

I kēia manawa, ua hoʻohana nui ʻia nā derivatives. hanauna II sulfonylureas, nona nā Gliclazide, no ka mea ʻoi aku lākou i nā lāʻau lapaʻau o ka hanauna i hala ma ka uha o ka hopena hypoglycemic, no ka mea, ʻo ka pilina a me ka ʻeka o ka ʻβ-cell, he 2-5 mau manawa kiʻekiʻe aʻe, e hiki ai ke hoʻokō i ka hopena i ka wā e hoʻopuka ai i nā kikoʻī loa. ʻO kēia hanauna o nā lāʻau lapaʻau e emi iki i nā hopena o nā ʻaoʻao.

ʻO kahi hiʻohiʻona o ka lāʻau lapaʻau ka hoʻohālikelike i kekahi mau metabolites i ka wā o nā hoʻololi metabol, a ʻo kekahi o ia mea he hopena koʻikoʻi ma ka microcirculation. Ua hōʻike nā nui noiʻi i kahi hōʻemi o nā hoʻopiʻi mikrovascular (retinopathya nephropathy) ma ka lapaau gliclazide. ^ E Ha yM. Ua emi ke kaumaha hoʻōla, hoʻomaikaʻi ke kōpāpale conjultival, nalo vasis stasis. ^ E Ha yM. ʻO ia ke kumu i kuhikuhi ʻia no nā ʻōwili maʻi mellitus maʻiʻi (hoʻōla, nephropathyme ka loaʻa ʻole o ka maʻi maʻamau retinopathies) a ua hōʻike ʻia e nā mea maʻi nā mea, no kēia kumu i hoʻohuli ʻia e lawe i kēia lāʻau lapaʻau.

Hoʻomaopopo nā mea he nui e lawe i nā papa ma hope o ka ʻaina kakahiaka, he nui ka nui o nā palaka, ʻo ka pōloli i ka lā a ʻae ʻole ʻia. Inā ʻaʻole, i ke kūleʻa ʻana o kahi meaʻai haʻahaʻa-haʻahaʻa a ma hope o ka hana kino kino, hiki nō ka hoʻomohala ʻana hypoglycemia. ^ E Ha yM. Me ke kaumaha o ke kino, pono ia e hoʻololi i ka nui o ka lāʻau. Ma hope o ke inu ʻana i ka waiʻona, ua loaʻa kekahi i nā kūlana hypoglycemic.

Hoʻohana nui ka poʻe pākeke i nā lāʻau lapaʻaka hypoglycemic, no ka mea, ua mahuahua ko lākou pilikia o ka ulu ʻana i ka hypoglycemia. I kēia pilina, ʻoi aku lākou ma mua o ka hoʻohana ʻana i nā lāʻau lapaʻau pōkole lima maʻamau (maʻamau gliclazide).
Hoʻomaopopo ka poʻe maʻi i kā lākou loiloi i ka leʻaleʻa o ka hoʻohana ʻana i nā papa hoʻokuʻu i hoʻololi ʻia: hana maikaʻi a lōlō, no laila ua hoʻohana ʻia lākou i hoʻokahi manawa i ka lā. Eia kekahi, ʻoi aku ka maikaʻi o kāna hōʻino ʻia ma mua o 2 mau manawa ma mua o ka hopena maʻamau gliclazide.

Aia nā hōʻike ma hope o kekahi mau makahiki (mai 3 a 5 mai ka hoʻomaka ʻana o ka waiwai) i ke kūʻē ʻia ʻana - he hōʻemi a he hapa ʻole o ka hana a ka lāʻau lapaʻau. I kēlā mau kūlana, ua koho ke kauka i nā hui pū me nā mea hoʻohana hypoglycemic ʻē aʻe.

Hiki iā ʻoe ke kūʻai i ka lāʻau lapaʻau i loko o ka pāna lāʻau lapaʻau o nā kūlanakauhale a pau o Lūkia: Ryazan, Tula, Saratov, Ulyanovsk.

Pehea e hana ai ka lāʻau lapaʻau?

ʻO ka hopena lāʻau lapaʻau he hypoglycemic. Hoʻonui i nā mea huna insulin e nā cell beta pancreatic a hoʻomaikaʻi i ka hoʻohana ʻana i ka glucose. Hoʻowalewale i ka hana o nā kinohi glycogen synthetase. Pōlaʻi i ka metabolic latent diabetes mellitus, i loko o nā mea maʻi me ka momona uluhua exogenously. Hoʻololiʻo Gliclazide i ka kiʻi glycemic ma hope o kekahi mau lā o ka mālama ʻana.

Hoʻopau ke Glyclazide i ka manawa mai ka manawa manawa a ka hoʻomaka ʻana i ka huna ʻana i ka insulin, e hoʻihoʻi i ka mua o ka neʻe o ka huna ʻana i ka insulin, a hoʻēmi ʻia i ka hyperglycemia i hoʻoiho ʻia e ka ʻai.

Nui! Hoʻoulu i nā metala hematological, nā waiwai rheological o ke koko, ka mea kiʻekiʻe a me nā ʻōnaehana microcirculation.

Mālama ʻo Gliclazide i ka hoʻomohala ʻana o ka microvasculitis, ʻo ia hoʻi hana ʻino o ka ʻina o ka maka. Kāohi ia i ka hoʻohui platelet, hoʻonui nui i ka ʻikekahi dissgregation index, hoʻonui i ka heparin a me ka hana fibrinolytic, a hoʻonui i ka hoʻololi heparin. Hōʻike i nā mea antioxidant, hoʻomaikaʻi i ka vascularization conjunctival, hoʻolako i ke kahe koko mau loa i nā microvessels, nā pae o nā hōʻailona o ka microstasis.

I ka nephropathy maʻi, hōʻemi ka lāʻau i ka proteinuria. Hoʻopili maikaʻi a paʻa koke mai ka hana o ka digestive tract. I loko o ka puʻuwai, e hoʻomoʻi ʻia ka maʻi oxidation me ka hoʻokumu ʻana o nā metabolites, ʻo kekahi o ia mea i hōʻike ʻia i ka microcirculation. Hoʻokuʻu ʻia ia i ke ʻano o nā metabolites me ka urine a ma o ke kaomi ʻana o ka digestive tract.

Nā ʻōlelo kikoʻī no ka hoʻohana

ʻO ka ʻōlelo mua loa no nā poʻe maʻi a hiki i ka 65 mau makahiki he 80 mg / lā, ma ʻelua mau puʻupaʻa i hoʻokaʻawale, no nā mea maʻi ma mua o 65 mau makahiki o ka makahiki, pono e hoʻomaka ka mālama ʻana i ka 40 mg 1 r / lā inā pono, e hoʻonui ʻia ka mana glycemic e hoʻonui ʻia i ka lā helu i kēlā me kēia lā i ka BPF (ʻōlelo no ka hoʻohana ʻana i nā lāʻau lapaʻau ma ka Pelekane. Puka Lahui, Lahui 60).

Hoʻomaopopo ʻia e hoʻonui i ka maʻi me kahi manawa o ka liʻiliʻi o 14 mau lā, ʻo ka awelika o kēlā me kēia lā he 80-240 mg i nā iniha ʻelua, ʻo ke ʻano maʻamau ka 160 mg / lā o BNF i nā pona ʻelua, ʻo ka nui loa ka nui o kēlā me kēia lā he 320 mg o BNF Glyclazide i ʻelua mau kala.

No nā papa kāpae i hoʻololi ʻia, ʻo ka inake hoʻomaka hoʻomaka ʻana he 30 mg. ʻO 30 ka nui o kēlā me kēia lā he 30-120 mg, lawe ʻia ka lāʻau maʻamau i kēlā me kēia lā i ka wā kakahiaka.

Pono e luku ʻia nā papa āpau, inā pono e hoʻoikaika i ka mālama ʻana i ka glycemia, hiki ke hoʻonui ʻia ka nui o ia lā i 60 mg, 90 mg a 120 mg i ka wā kakahiaka kakahiaka, ʻo ia ka mea e hoʻolōʻihi i ka pā, me ka wā o ka 1 mahina, koe wale nō ke emi ʻana ka hūnā me ka glucose koko i loko o 2 mau pule o ka mālama ʻana.

I kēlā mau kūlana, hiki ke hoʻonui ʻia ke ʻano ma hope o 2 mau pule o ka mālama ʻana, ʻo ka awelika o kēlā me kēia lā he 60 mg / lā i hoʻokahi manawa.

Nui! Ma mua o ka hoʻonui ʻana i nā lā i kēlā lā i kēia lā nā lāʻau lapaʻau, e kamaʻilio me kāu kauka.

I ka wā kakahiaka kakahiaka nui, no ka hapanui o nā maʻi mai ka hoʻomaka mua o ka mālama ʻana, ʻo ka nui e ʻōlelo ʻia ana ʻo ia i kēlā me kēia lā he 120 mg 1 papa. (Nā ʻ )lelo) me kahi hoʻokuʻu i hoʻololi ʻia i ka lāʻau lapaʻau 60 mg i like me 2 papa me kahi hoʻokuʻu i hoʻololi ʻia o ka lāʻau 30 mg o ka papaʻaina.

Nā papa kahi i hoʻoneʻe ʻia o ka lāʻau lapaʻau 60 mg ma lalo o ka ʻāpana, hiki iā ia ke hoʻohana i ka lāʻau lapaʻau ma ke ʻano o 30 mg (1/2 papa.) A ma kahiʻu o 90 mg.

Hoʻololi i ka mea maʻi mai nā hoʻomākaukau e pili ana iā Glyclazide 80 mg i kahi mākaukau e loaʻa ana i nā papa o nā Gliclazide 60 mg i hoʻokuʻu ʻia: 1 papa e loaʻa ana iā Glyclazide 80 mg e pili ana i ka papa ʻaina 1/2. ka lāʻau lapaʻau he 60 mg.

Pehea e mālama ai i ka wā hāpai

I ka wā hapai, ua hoʻohālikelike ʻia ʻo Glyclazide, no laila ke hoʻohana ʻia nei i kēia wā hana a me ka lactation.

I ka wā hapai, hiki ke hele mai kahi kūlana o ka hoʻohaʻahaʻa glucose, ka mea e hiki ke alakaʻi i nā hopena like ʻole a ʻoluʻolu loa i ka wā e hoʻohana ai iā Glyclazide i ka wā hāpai. No laila, i ka wā hāpai, ua manaʻo ʻia e hana i kahi hōʻike hoʻoliʻi glucose.

Ma ka maʻi ʻaʻai, he mea koʻikoʻi loa ia ka kiaʻi ʻana i ke kiʻekiʻe o ke kō i ke koko, hiki ke kōkua ʻia e ka glucometer, ua hōʻike ʻia ma ka kikoʻī o ka ʻatikala "Ka wehewehe piha ʻana o ka Accu-Chek Active glucometer".

ʻŌpū a me ka lactation

ʻAʻoheʻike iʻike me ke koho ʻana o ka Gliclazide MV i nā wahine hāpai. ʻAʻole hōʻoia nā haʻawina i nā holoholona i ka hele ʻana o nā hopena teratogenic o kēia ʻano. Me ka lawa ʻole o ka uku ʻana no ka diabetes mellitus i ka wā mālama, loaʻa ka hopena i ka ulu ʻana o ka nui o nā mau huaʻāina i loko o ka pūpū, kahi e hiki ai ke hōʻemi ʻia e ka mākaʻi glycemic kūpono. Ma kahi o gliclazide i nā wahine hāpai, ua kuhikuhi ʻia e hoʻohana i ka insulin, ʻo ia hoʻi ka lāʻau lapaʻau ke koho pono ʻana no nā maʻi e hoʻolālā nei i kahi hapai, a i nā mea hoʻi i hāpai i ka wā mālama me ka Gliclazide MV.

No ka mea, ʻaʻohe ʻike e pili ana i ka komo ʻana o ka hana ikaika o ka lāʻau i ka waiū umauma, a ma nā mea hānau keiki hou, he nui ka nui o ka ulu ʻana o ka hypoglycemia neonatal, ka lawe ʻana i ka Gliclazide MB i ka wā lactation a contraindicated.

Nā hopena ʻaoʻao a me ka overdose

1. Mai ka pūnaehana hana ʻana, hiki i ka Glyclazide ke kumu: ʻaʻohe - anorexia, nausea, luaʻi, huʻi, ʻeha o ka epigastric.
2. Mai ka ʻōnaehana hemopoietic: i kekahi mau hihia - thrombocytopenia, agranulocytosis a o leukopenia, anemia (maʻamau hoʻi hoʻohuli).
3. Mai ka ʻōnaehana endocrine: me kahi overdose - hypoglycemia.
4. Nā maʻi kūlou: ʻāwili ka ʻili, ʻeha.

Hōʻike ʻia ka overdose e nā hōʻailona o ka hypoglycemia: ʻeha, kaʻeha, ka nāwaliwali koʻikoʻi, nā luhi, ka palpitations, ka nui o ke koko, arrhythmia, ka hiamoe, ke kuʻi ka huhū, ka huhū, ka huhū, ka lohi ʻana, ka nānāʻana a me ka haʻi, ka haʻalulu, ka ʻeha, ka hōʻino, ka bradycardia, ka nalowale o ka ʻike.

ʻO kekahi o nā hōʻailona weliweli loa he coma.

Nui! Ke hoʻohana ʻia nā lāʻau lapaʻau, pono ʻoe e kiaʻi i kou kūlana.

Me ka hypoglycemia maʻalahi me ka ʻike ʻole ʻole o ka ʻike, hoʻemi i ka nui o ka lāʻau o ka lāʻau a hoʻonui i ka nui o nā karoli e hāʻawi ʻia ana me ka meaʻai.

I nā kūlana hypoglycemic koʻikoʻi, pono ka mālama hospitalization a me ke kōkua ʻana: iv 50 ml o kahi hoʻonā glucose 20-30%, a laila he 10% dextrose a i ʻole ka hopena glucose i ka wai. I loko oʻelua mau lā, ka kiaʻi ʻia ka pae glucose. ʻAʻohe kūpono ʻo Dialysis.

Nā hōʻike a me ke kumukūʻai

ʻO nā mea hoʻohālike Gliclazide:

• Vero-Kauahi
• Holaʻula
• Luna Hoʻolima,
• Hōʻea
• Luna Hue
• Glyclazide-Akos,
• Glioral
• Hula,
• Kālai
• Diabetalong
• Diabeton
• Imi Diabeton MV,
• Hoʻopape
• Kahiki Diabefarm,
• Diabinax
• Diabresid
• Nā Diula
• Medoclacid
• Prediania
• Hoʻololi.

Hiki iā ʻoe ke kūʻai i ka lāʻau ma ka mākeke olakino o nā kūlanakauhale a pau o Rūsia.

Hiki ke kūʻai aku iā Glyclazide MV 30 mg no 115-147 mau rubles.

Mahalo i kēia ʻatikala, hiki iā ʻoe ke aʻo hou e pili ana i nā lāʻau lapaʻau maʻi type II o nā makahiki hou.

Nā Hōʻike Kokua

I kēia manawa, ʻike nui ʻia nā derivatives o ka sulfonylureas o ka hanauna II, kahi a Gliclazide e hoʻohana nui ʻia no ka mea ua ʻoi aku lākou i nā lāʻau lapaʻau o ka hanauna ma mua o ka hopena o ka hopena hypoglycemic, ʻoiai ka mea e pili ai i nā mea ʻalaʻelima β-cell he 2-5 mau manawa kiʻekiʻe, e hiki ai ke hoʻokō i ka hopena ke kuhikuhi ʻana i nā palena liʻiliʻi . ^ E Ha yM. ʻO kēia hanauna o nā lāʻau lapaʻau e emi iki i nā hopena o nā ʻaoʻao.

ʻO kahi hiʻohiʻona o ka lāʻau lapaʻau ka hoʻohālikelike i kekahi mau metabolites i ka wā o nā hoʻololi metabolic, a ʻo kekahi o lākou he hopena koʻikoʻi ma ka microcirculation. Ua hōʻike nā haʻawina he nui i ka hōʻemi ʻana i ka hopena o nā hoʻopiʻi o kā microvascular (retinopathy a me nephropathy) i ka mālamaʻana o gliclazide.

Pono e ʻike! Pēlā nō hoʻi, e hoʻomaikaʻi iā Glyclazide, ua emi ka nui o ka angiopathies, e holomua ka mea kanu o ka conjunctiva, a laila hele aku ka vascular stasis.

ʻO ia ke kumu i kuhikuhi ʻia no nā hoʻopiʻi o ka maʻi mellitus (angiopathy, nephropathy me ka hoʻomaka ʻana o ka renal opole maʻamau, retinopathy) a ua hōʻike ʻia kēia e nā mea maʻi nā mea, no kēia kumu, i lawe e lawe i kēia lāʻau.

Hoʻomaopopo nā mea he nui e lawe i nā papa ma hope o ka ʻaina kakahiaka, kahi i loaʻa ka nui o nā palaka, ʻo ka pololi i ka lā i ʻae ʻole ʻia. Inā ʻaʻole, i ke kūleʻa ʻana o kahi papa haʻahaʻa o ka lālani a ma hope o ka hoʻoikaika kino loa, hiki i ka hoʻomohala ʻana o ka hypoglycemia.

Me ke kaumaha o ke kino, pono ia e hoʻololi i ka nui o ka lāʻau. Ma hope o ke inu ʻana i ka waiʻona, ua loaʻa kekahi i nā kūlana hypoglycemic.

Hoʻohana nui ka poʻe pākeke i nā lāʻau lapaʻaka hypoglycemic, no ka mea, ua mahuahua ko lākou pilikia o ka ulu ʻana o ka hypoglycemia. I kēia pili, ʻoi aku lākou ma mua o ka hoʻohana ʻana i nā lāʻau lapaʻau pōkole (gliclazide maʻamau).

Hoʻomaopopo ka poʻe maʻi i kā lākou loiloi i ka leʻaleʻa o ka hoʻohana ʻana i nā papa hoʻokuʻu i hoʻololi ʻia: hana maikaʻi a lōlō, no laila ua hoʻohana ʻia lākou i hoʻokahi manawa i ka lā.Eia kekahi, ʻoi aku ka maikaʻi o kona kūʻai ʻo 2 mau manawa ma mua o ka hopena o ka gliclazide maʻamau.

Aia nā hōʻike ma hope o kekahi mau makahiki (mai 3 a 5 mai ka hoʻomaka ʻana o ka waiwai) i ke kūʻē ʻia ʻana - he hōʻemi a he hapa ʻole o ka hana a ka lāʻau lapaʻau. I kēlā mau kūlana, ua koho ke kauka i nā hui pū me nā mea hoʻohana hypoglycemic ʻē aʻe.

Nui! Ke hoʻohana nei iā Glyclazide, e like me nā lāʻau lapaʻau ʻē aʻe, pono ʻoe e kamaʻilio i kāu kauka.

Ma ke ʻano he adjuvant hou no ka maʻi maʻi o ka lua, i hui pū ʻia me ka ʻai kūpono, hana maikaʻi ʻia. ʻIke wau i ka maikaʻi a nānā maikaʻi, makemake wau i ke kumukūʻai a me kaʻole o nā hopena ʻaoʻao, ka hopena maoli.

Pono nā mea āpau, ʻaʻole i emi iho ke kō. Ua inu au ma kahi o 30 mau kāleka, ʻaʻole i hāʻule kaʻa, akā hoʻonui. Hoʻomaka wau e inu i nā ʻāpana he 60. ua hoʻomaka ʻia kahi puʻuwai ikaika, kū a ke piʻi. ʻAʻohe paha pōpoki i hiki mai nō. A i ʻole nā ​​ʻē aʻe ʻē aʻe. No laila, kūʻai ʻoe i nā lāʻau ʻē aʻe iā ʻoe iho.

Hoʻohui nūhou

Me ka hoʻohana pū ʻana o Gliclazide MV me kekahi mau lāʻau lapaʻau, hiki i nā hopena kūpono ʻole:

• Nā derivava Pyrazolone, salicylates, phenylbutazone, sulfonamides antibakteri, theophylline, caffeine, monoamine oxidase inhibitors (MAOs): potentiation o ka hopena hypoglycemic o glyclazide,
• ʻO nā beta-blockable non-koho: hoʻonui nui aʻe o ka hypoglycemia, hoʻonui nui ʻana a me ka masking o ka tachycardia a me nā lima pākuʻi i hōʻike ʻia o ka hypoglycemia,
• ʻO Gliclazide a me ka acarbose: hoʻonui i ka hopena hypoglycemic,
• Cimetidine: hoʻonui i ka kukuna plasma gliclazide (ulu ulu hypoglycemia, hōʻike ʻia i loko o ke ʻano o ka hopohopo o ke kikowaena o ka pūnaehana a me ka ʻike naʻau).
• ʻO nā Glucocorticosteroids (me nā puka i waho o nā ʻano aʻi aku), diuretics, barbiturates, estrogens, progestin, hui pū kekahi estrogen-progestogen, diphenin, rifampicin: kahi hōʻemi i ka hopena hypoglycemic o ka glycazide.

ʻO nā analogues o Gliclazide MV lākou: Gliclazide-Akos, Glidiab, Glidiab MV, Glucostabil, Diabeton MV, Diabefarm MV, Diabinax, Diabetalong.

Nā Hōʻikeʻike i ka Gliclazide MV

ʻO Gliclazide MV no ka derivatives sulfonylurea o ka lua o ka hanauna a ke hōʻike ʻia nei e kahi nui koʻikoʻi o nā hana hypoglycemic, kahi i wehewehe ʻia e kahi kiʻekiʻe kiʻekiʻe no nā ʻae-cell-cell (2-5 mau manawa i ʻoi aku ma mua o ka hanauna o nā lāʻau lapaʻau). Hāʻawi kēia mau waiwai iā ʻoe e hoʻokō i kahi hopena therapeutic me nā dosis liʻiliʻi a hōʻemi i ka nui o nā hopena maikaʻiʻole.

Wahi a nā loiloi, hoʻohana ʻia ʻo MV Gliclazide no nā hoʻopiʻi o ka maʻi mellitus o ka maʻi mellitus (retinopathy, nephropathy me ka hoʻomaka ʻole o ke aʻalolo maʻamau, angiopathy). Ua hōʻike ʻia kēia ma nā mea maʻi i lawe ʻia e loaʻa i kēia lāʻau lapaʻau. ʻO kēia no ka mea, ʻo kekahi o nā metabolits glycazide e hoʻopilikia nui i ka microcirculation, hoʻemi i ka hōʻeha o ka angiopathy a me ka pilikia o ka hoʻomohala ʻana i nā hoʻopiʻi microvascular (nephropathy a me ka retinopathy). I ka manawa like, hoʻomaikaʻi hou ke kahe koko i loko o ka conjunctiva a nalowale nā ​​vascular stasis.

Hoʻolaha nā loea he nui i ka wā o ka mālama ʻana me Gliclazide MV, pono e pale i ka pōloli a hāʻawi i ka makemake i nā meaʻai me nā momona. Inā ʻaʻole, i ka wā o ke kīhina o kaʻai haʻahaʻa o ka lālani a ma hope o ka hoʻoikaika kino loa, hiki i ka mea maʻi ke hoʻomohala i ka hypoglycemia. Me ke kaumaha o ke kino, pono ke hoʻoponopono ʻia. I kekahi mau mea maʻi, ma hope o ka inu ʻana i ka waiʻona i ka wā o ka mālama ʻana me Gliclazide MV, ua ʻike pū ʻia nā hōʻailona o ka hypoglycemia.

ʻAʻole i ʻōlelo ʻia ʻo Gliclazide MV no ka hoʻohana ʻana i nā maʻi maʻi elemakule e ulu aʻe ana no ka ulu ʻana o ka hypoglycemia, no laila, i kēia hihia, kūpono ke hoʻohana i nā lāʻau lapaʻau ʻōkole.

Hoʻomaopopo ka poʻe maʻi i ka hōʻoluʻolu o ka hoʻohana ʻana i ka gliclazide i ke ʻano o nā papa hoʻoneʻe i hoʻololi ʻia: hana maʻalahi lākou, a ke kāʻei wale ʻia ka mea hana a pau ma ke kino. Ma muli o kēia, hiki ke lawe ʻia ka lāʻau lapaʻau i hoʻokahi manawa i kēlā me kēia lā, a ʻo kāna hōʻola a me nā lā therapeutic he 2 mau manawa e emi iho ai ma mua o kahi ʻano gliclazide maʻamau. Aia nō hoʻi nā hōʻike e pili ana i ka hoʻomehana lōʻihi (3-5 mau makahiki mai ka hoʻomaka ʻana o ka hoʻokele), i hoʻomohala kekahi mau mea maʻi, e koi ai i ka hana ʻana o nā lāʻau lapaʻau hou.

Pākuʻi helu

30 mg a me 60 mg o ka papa i hoʻokuʻu ʻia

Aia i loko o hoʻokahi papa:

mea waiwai - gliclazide 30.0 mg a 60.0 mg,

nā mea hoʻowalewale: ʻO ka silica o ka silikua kaomi silodyous, hydroxypropyl methylcellulose, sodium stearyl fumarate, talc, lactose monohala.

Ke keʻokeʻo a ʻele paha keʻokeʻo nā papa ʻulaʻula, e puni ana i ke ʻano me ka wai cylindrical a me kahi bevel (no kahi dosis o 30 mg).

Ke keʻokeʻo a ʻele paha keʻokeʻo nā papa ʻulaʻula, e puni ana i ke ʻano me ka wai cylindrical, facet a me ka notch (no kahi dosis o 60 mg).

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau

Ma hope o ka lawelawe waha, ua hoʻopili piha ʻia ka gliclazide mai ka ʻeha gastrointestinal. ʻAʻole ʻai i ka ʻai ʻana i ke kiʻekiʻe o ka inu ʻana. Māhuahua ka holomua o ka gliclazide i ka plasma i ka holo mua o nā hola 6 ma hope o ka hoʻokele ʻana a hiki i ka pākaʻi e hoʻomau ana mai ka 6th a 12 mau hola. He haʻahaʻa loa ka ʻano o ka pālua pālua. ʻO ka pilina ma waena o ke kinikini a hiki i ka 120 mg a me ka pihi kukū plasma o ka lāʻau lapaʻau he laina hilinaʻi kaila. ʻO ka 95% o ka lāʻau lapaʻau ka mea e hoʻopili ai i nā protein plasma.

Hoʻomo ka nui o ka Gliclazide i loko o ka pēpē a hoʻoulu ʻia i ka nui o ka pā. Lawe ʻia ka hoʻomaʻamaʻa ʻana i nā pōkoki ma nā ʻano o nā metabolites, emi mai ka 1% i hoʻololi ʻia i loko o ka urine. ʻAʻohe huahana metabolites ikaika i loko o ka plasma.

ʻO ka hapalua-ola (T1 / 2) o nā gliclazide kahi a 16 mau hola (12 a 20 mau hola).

I ka poʻeʻelemakule, ʻaʻohe mau loli nui i ka lāʻau pharmacokinetic.

ʻO ka awelika pākahi o kēlā me kēia lā o 60 mg e hāʻawi ana i ka neʻe o ka maikaʻi o ka gliclazide i loko o ka plasma no kahi o 24 mau hola.

Lapaʻau lāʻau

ʻO Gliclazide MV kahi lāʻau lapaʻau hypoglycemic waha mai ka hui o II Generation sulfonylurea derivatives, kahiʻokoʻa mai nā lāʻau like ʻole ma ke kahe ʻana o ka hā heterocyclic N-loaʻa me ka mea paʻa endocyclic.

Hoʻopau ka Gliclazide MB i ka pae o ka glucose i ke koko, ke hoʻoikaika nei i ka mea ʻona o ka insulin e ka β-cells of islets of Langerhans. Ma hope o 2 mau makahiki o ka mālama ʻana, loaʻa nō ka hapa nui o nā mea maʻi e hoʻonui i ka pae o ka insulin postprandial a me nā mea huna o C-peptides.

Ma ke ʻano 2 diabetes mellitus, hoʻōla hou ka lāʻau lapaʻau i ka piʻi koke o ka mea huna o ka insulin i ka pane ʻana i ka hoʻokomo o glucose a hoʻonui i ka lua o ka ʻikepili o ka insulin. Hoʻonui ʻia ka hoʻonui nui o ka huna ʻana i ka insulin i ka pane ʻana i ka hoʻoulu ʻana ma muli o ka ʻai kai a me ka hoʻokele glucose.

He hopena o Gliclazide MV ma ka microcirculation. Hoʻēmi i ka hōʻemi o ka trombosis hoʻokahe koko liʻiliʻi, e hoʻopilikia ai i nā hana ʻelua i hiki ke komo i ka hoʻomohala ʻana o ka hoʻopiʻi i ka maʻi mellitus. vascular endothelium a me ka hoʻonui ʻana i ka hana o ke kiko plasminogen activator.

ʻLoe a me ke kākele

No ka lawelawe waha. Ke koho ʻia ka lāʻau lapaʻau wale nō no ka mālama ʻana i nā pākeke.

Hiki i ka maʻi maʻamau o kēlā me kēia lā ʻo MV Glyclazide mai 30 mg a 120 mg. Hoʻonohonoho ʻia e lawe i hoʻokahi manawa i ka lā ma ke kakahiaka kakahiaka, hoʻomaloʻo i ka papa papaʻa (s) piha me ka ʻole o ka ʻikā.

Inā hele ʻoe i ka inu i ka lāʻau lapaʻau, ʻaʻole hiki iā ʻoe ke hoʻonui i ka nui aʻe i ka lā aʻe.

E like me nā lāʻau lapaʻau hypoglycemic ʻē aʻe, pono ke koho pono ʻia ka nui o kēia lāʻau i kēlā me kēia hihia, i ka hopena o ka metabolic o ka mea maʻi.

ʻO ka paipai hoʻomaka ʻia he 30 mg i kēlā me kēia lā.

I ka hihia o ka mālama pono o ka nui o ka glucose o ke koko, hiki ke hoʻohana ʻia kēia lāʻau ma ke ʻano he mālama mālama.

Ināʻaʻa ʻaʻole pono ka nui o ka pae o ka glucose, hiki ke piʻi ikaika ka nui ma kahi o 60 mg, 90 mg a 120 mg i kēlā me kēia lā. ʻO ka manawa ma waena o ka hoʻonui mauʻana i ka hopena o ka lāʻau e pono ka liʻiliʻi loa ma kahi o hoʻokahi mahina, ke ʻole emi ka nui o ka glucose koko ma hope o nā hebedoma ʻelua o ka lapaʻau. I kēlā mau kūlana, hiki ke hoʻonui ʻia ke ʻano i ʻelua mau pule ma hope o ka hoʻomaka ʻana o ka mālama ʻana.

ʻO ka dosis kiʻekiʻe loa i ʻōlelo ʻia i kēlā me kēia lā he 120 mg.

Ke hoʻololi ʻana mai kekahi lāʻau lapaʻau hypoglycemic ʻē aʻe iā MV Gliclazide

Ma ka hoʻololi hou, pono e noʻonoʻo ʻia ka nui a me ka hapalua o ke ola ma mua. ʻAʻole koi ʻia kahi manawa hoʻololi. Hoʻomaka ʻia ʻo ka hoʻohana ʻana o Glyclazide MV me 30 mg, ukali ʻia e ka hoʻoponopono ʻana ma muli o ka hopena metabolic.

Ke hoʻololi nei i nā lāʻau lapaʻau'ē aʻe o ka pūʻulu sulfonylurea me kahi hapalua hapalua ola, i mea e pale aku ai i ka hopena hoʻohui o nā mea ʻelua, hiki ke koi ʻia i ka manawa kīnā ʻole i kekahi mau lā. I kēlā me kēia pilikia, pono ka hoʻololi ʻana i nā papa Glyclazide MV me kahi neʻe mua ʻana o ka pualikua mua o 30 mg, ukali ʻia e ka nui phased ma ke ʻano, e pili ana i ka hopena o ka metabolic.

Hoʻohana me ka hui pū me nā lāʻau lapaʻau antidiabetic

Hiki ke hoʻohana i ka Gliclazide MB i ka hui pū me ka biguanides, alpha-glucosidase inhibitors a i ʻole insulin. I nā maʻi e loaʻa ʻole i ka pae koko o ka nui o ka glucose e ka Gliclazide MV, hiki ke kuhikuhi ʻia i kahi lāʻau o ka insulin i lalo o ka mākaʻi o kekahi kauka.

Keiki (ma luna o 65 mau makahiki)

Nā kīnā o ka lāʻau lapaʻau i ka poʻe ʻelemakule e like nō me ia no nā mea pākeke ma lalo o ka 65 mau makahiki o ka makahiki.

ʻO nā ʻōnaʻi o ka lāʻau no ka hiki ʻole o ke kīleʻa i ke kaumaha me ka hōʻino ʻana i ke ʻano o ka hōʻeha ʻokoʻa i nā poʻe no ka poʻe me ka hana maʻamau.

ʻO nā maʻi i ka hoʻonui ʻia ʻana o ka Hypoglycemia

Ma kahi o ka kīnā ʻole lawa a kūpono ʻole, i ka hōʻeha ʻana o ka hopena endocrine koʻikoʻi a maikaʻi ʻole paha (hypopituitarism, hypothyroidism, paʻa o ka hormone adrenocorticotropic), ma hope o ke kau ʻana i ka hopena o ka corticosteroid ma mua a i ʻole ka hopena, pale i nā maʻi vascular), ʻoi ʻia e kuhikuhi i ka lāʻau lapaʻau me ka liʻiliʻi haʻahaʻa o kēlā me kēia lā o 30 mg.

Hoʻopili i nā lāʻau lapaʻau

Ke hōʻemi nei i nā hopena i hoʻonuiʻia i ka hopena o Gliclazide MV (hoʻonui i ka ikehu o ka hypoglycemia)

ʻO Miconazole (i ka wā i lawelawe ʻia ai i ʻole hoʻohana ʻia i ka mucosa o ka waha waha i loko o ke ʻano o ke kala): hoʻonui i ka hopena hypoglycemic o MV Gliclazide (hypoglycemia e ulu a hiki i ka hypoglycemic coma).

ʻAʻole ia e koi ʻia no ka hoʻohana ʻana:

Hoʻonui ka Phenylbutazone i ka hopena hypoglycemic derolatives o ka sulfonylurea (neʻe iā lākou mai ka kamaʻilio ʻana me nā protein plasma a / a i ʻole a lohi i kā lākou mauʻu mai ke kino).

ʻOi aku ka maikaʻi e hoʻohana i kekahi lāʻau lapaʻau anti-inflammatory.

Hoʻonui ka waiʻona i ka hypoglycemia, ke kāohi nei i nā pane compensatory, hiki ke hoʻopili i ka hoʻomohala ʻana o ka comog hypoglycemic.

Pono e haʻalele i ka hoʻohana ʻana i ka waiʻona a me ka lawe ʻana i nā lāʻau lapaʻau, kahi i loaʻa ka waiʻona.

Nā hui e koi ana i ka mālama ʻana:

ʻO ka hoʻohana like ʻana o kēia mau lāʻau i hiki ke hoʻonāukiuki i ka hopena hypoglycemic o ka lāʻau Gliclazide MV a i kekahi mau hihia ke alakaʻi i ka hoʻomaka ʻana o ka hypoglycemia:

nā mea āpau antidiabetic (insulins, acarbose, biguanides), beta-blockers, fluconazole, angiotensin-hoʻohuli i ka hoʻohui o enzyme (captopril, enalapril), H2 receptor antagonists, inhibitors monoamine oxidase irreversible (MAO I), sulfonamides a me nā lāʻau lapaʻau anti-inflammatory non-steroidal.

Ke hōʻemi nei nā lāʻau lapaʻau Glyclazide MV-nawaliwali

ʻAʻole ia e koi ʻia no ka hoʻohana ʻana:

ʻAʻole kōkua ʻia ka hoʻohana ʻana i ka huizol ma muli o ka loaʻa o ka piʻi o ka glucose koko. Inā hikiʻole ke hōʻole i ka hoʻohana ʻana o ka danazol, a laila wehewehe i ka mea maʻi i ka nui o ka pale ʻana i ka kao o ka glucose i loko o ke koko a me ka hoʻonaninani. I kekahi manawa e koi ana e hoʻoponopono i ke ʻano o ka Gliclazide MV i ka manawa a ma hope o ka hoʻomau ʻana o nā danazol.

Nā hui e koi ana i ka mālama ʻana:

ʻO Chlorpromazine ma nā keke kiʻekiʻe (ʻoi aku ma mua o 100 mg i kēlā me kēia lā) hoʻonui i ka nui o ka glucose i loko o ke koko, e hoʻemi ana i ka mea huna o ka insulin.

ʻO Glucocorticosteroids (ke ʻōnaehana a me ka noiʻi kūloko: intraarticular, ka ʻili a me ka hoʻoponopono ʻīkī) a me ka tetracosactrin e hoʻonui i ka hoʻoliʻi koko me ka hoʻomohala hiki i ka ketoacidosis, ma muli o kahi ka hoʻohaʻahaʻa ʻana i ka hoʻohaʻahaʻa kalika e nā glucocorticosteroids.

β2-adrenostimulants - ritodrin, salbutamol, terbutaline (hoʻohana i ʻōnaehana system) i mea e hoʻonui ai i ka pae o ka glucose.

E makaʻala pono i ka mea nui o ka mālama ponoʻina ʻana o ka glucose koko. Inā pono, e hoʻokaʻawale i ka mea maʻi i ka therapy insulin.

Inā pono ʻoe e hoʻohana i nā hoʻohui ma luna, pono e mālama pono i ka mālama ʻana i nā pae glucose koko. He mea pono paha ia e hoʻoponopono hou i ka hapa o MV Glyclazide ʻelua i ka wā hui pū ʻana a ma hope o ka hoʻokuʻu ʻana o ka lāʻau lapaʻau hou.

ʻO ke hui pū ʻana o ka Gliclazide MV me nā lāʻau anticoagulant (warfarin, etc.) hiki ke alakaʻi i ka hoʻonui i ka hopena anticoagulant o nā lāʻau. Hiki ke koi ʻia ka hoʻoponopono ʻo Anticoagulant.

Palapala palapala kākau inoa

JLLC "Lekpharm", Republic of Belarus, 223141, Logoysk, ul. Minskaya, 2a, tel / fax: +375 1774 53 801, e-mail: [email protected]

ʻLelo i ka hui e ʻae ana i nā kuleana mai nā mea kūʻai aku ma ka maikaʻi o nā huahana ma ke aupuni o ka Repubalika o Kazakhstan

ʻOihana Keʻena o ka Lekpharm COOO i ka Repubalika o Kazakhstan,

050065, ka Repubalika o Kazakhstan, Almaty, moku Almaly, ul. Kazybek bi, d. 68/70, kihi o st. Nauryzbay batyr, tel. 8 (727) -2676670, fax 8 (727) -2721178

ʻAau, inoa a me nā kikoʻi hoʻopili (kelepona, kelepona, leka uila) o ka hui i ka wahi o ke aupuni o Kazakhstan kuleana no ka hoʻopaʻa inoa ʻana i ka mālama ʻana i ka palekana olakino.

ʻOihana Keʻena o ka Lekpharm COOO i ka Repubalika o Kazakhstan,

050065, ka Repubalika o Kazakhstan, Almaty, moku Almaly, ul. Kazybek bi, d. 68/70, kihi o st. Nauryzbay batyr, tel. 8 (727) -2676670, fax 8 (727) -2721178,